Investigative Dermatology and Venereology ResearchInvestigative Dermatology and Venereology ResearchInvestigative Dermatology and Venereology ResearchInvestigative Dermatology and Venereology Research2381-0858Ommega Online PublishersNew Jersey, USA75810.15436/2381-0858.16.758Research ArticleAdemetionine in Different Combination Regimens to Treat Rosacea: Results from a Randomized, Prospective Clinical TrialAdemetionine in Different Combination Regimens to Treat Rosacea: Results from a Randomized, Prospective Clinical TrialKarl Patrick Goritz 1Dniepropetrovsk Medical Academy Dniepropetrovsk Ukraine 2Dnipropetrovsk State Cosmetology Hospital Dniepropetrovsk Ukraine 3Medical Center PP ldquo Lenomed rdquo Dniepropetrovsk Ukraine Editor* E-mail: tsvyat@rambler.ru
The authors have declared that no competing interests exist.
20161302201621IDVR-16-RA-75821012016090220162016Creative Commons Attribution LicenseThis is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Introduction Rosacea is characterized by transient or persistent facial erythema telangiectasia papules and pustules and is classified into 4 subtypes erythematoteleangiectatic stage I papulopustular stage II phymatous stage III and ocular rosacea Objective The study assessed the efficacy of different combinations of oral and topical medications combined or not with ademetionine in rosacea Methods This randomized open label prospective and exploratory study was conducted in 110 healthy male subjects of at least 18 years of age with stage I stage II or stage III rosacea Efficacy and safety of different basic BCR and complex basic regimen ademetionine CCR combinations of oral and topical rosacea medications were assessed throughout histopathological immunohistochemical and clinical methods Results Multiple combination regimens using topical and oral medications significantly improved stage I and stage II III rosacea Improvement on a histological immunohistochemical and clinical level was significantly superior p lt 0 05 when ademetionine was added Recurrence of stage I or stage II III rosacea was significantly less frequent p lt 0 05 in patients who received the CCR treatment regimens No systemic adverse event was observed Irritation was reported in 9 patients in the stage I group during the first 3 to 7 days of application of azelaic acid 15 gel 5 patients 16 7 in the CCR group and 4 patients 20 in the BCR group No local adverse events were reported in the stage II III patient group Conclusion Ademetionine may be a sparring partner in the treatment of rosacea using combination treatments 10